Lobaplatin inhibits prostate cancer progression in part by impairing <scp>AR</scp> and <scp>ERG</scp> signal

Chen, Lei; Cao, Hongwen; Yu, Chao; Feng, Yigeng

doi:10.1111/fcp.12377

Cited by 5 publications

(4 citation statements)

References 41 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, lobaplatin has been proven to inhibit the proliferation and peritoneal metastasis of colorectal cancer in phase II clinical trials [ 68 ], can also inhibit gastric cancer cells by inducing apoptosis [ 69 ], can effectively inhibit human non-small cell lung cancer cells in phase S, and triggers apoptosis in human non-small cell lung cancer [ 67 , 68 , 69 , 70 ]. In addition, lobaplatin has shown lower drug resistance in many malignancies compared with carboplatin and has lower drug toxicity in patients [ 71 ]. Lobaplatin is currently registered in China for the management of metastatic disease in breast cancer and small cell lung cancer SCLC.…”

Section: Metal Anticancer Drugsmentioning

confidence: 99%

Research Progress of Metal Anticancer Drugs

Bai,

Aodeng,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad.

show abstract

Section: Metal Anticancer Drugsmentioning

confidence: 99%

Research Progress of Metal Anticancer Drugs

Bai,

Aodeng,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Surgery and radiotherapy are commonly used to treat localized prostate cancer. If developed into metastatic prostate cancer, androgen deprivation therapy becomes the first‐line treatment in its initial phase . For HRPC, inhibition of cancer progression by blocking AR signals has been reported .…”

Section: Association Between Cp/cpps and Pca Immune Microenvironmentmentioning

confidence: 99%

Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines

Liu

Mikrani

Xie

et al. 2019

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Prostate cancer and prostatitis are both significant health concerns. A large number of studies have established that the occurrence of the two is closely related. However, the most common prostatitis, type III chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS), is reported to not correlate with the occurrence of prostate cancer. Although the etiology of CP/CPPS is unknown, it may be related to the autoimmune mechanism favored by most studies. Manipulating the immune system and targeting tumor microenvironment are promising new methods for the treatment of prostate cancer. Therefore, this review focuses on the immune cells and cytokines of CP/CPPS and prostate cancer from the perspective of biological immunology and immune microenvironment. We discuss T‐regulatory (Treg) and T helper 17 (Th17) cells dysfunction, the abnormal regulation of T helper 1(Th1) and T helper 2 (Th2) cells, macrophages, and their related cytokines as key activators in CP/CPPS. In addition, we discuss the roles of Treg and Th17 cells, Th1 and Th2 cells, and related cytokines in modulating prostate cancer progression. This review highlights the concept that immune cells and cytokines provide a research strategy for the etiology of CP/CPPS and offer potentially promising targets for the treatment of prostate cancer.

show abstract

“…Lobaplatin has exhibited promising therapeutic effects in several clinical studies; for example, it has been found to suppress proliferation and peritoneal metastasis in a preclinical model of colorectal cancer (11), to inhibit gastric cancer cells by inducing apoptosis (12), and to arrest cells in S phase and trigger apoptosis in the context of human non-small cell lung cancer (13). Furthermore, lobaplatin can be used to overcome the drug resistance associated with cisplatin observed in several types of cancer as it exhibits lower toxicity compared with cisplatin (14). Thus far, lobaplatin has been approved in China for the treatment of small-cell lung and metastatic breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo

et al. 2020

View full text Add to dashboard Cite

Retinoblastoma (RB) is one of the most aggressive malignancies affecting infants and children. Platinum drugs are commonly used in the treatment of RB; however, their efficacy is often compromised by drug resistance and severe toxicity. The present study aimed to investigate and compare the toxicity and antitumor activity of the third-generation platinum drugs, carboplatin and lobaplatin, in vitro and in vivo. The Y79 RB cell line was treated with carboplatin or lobaplatin in vitro and then used to establish xenografts in immunodeficient nude mice in vivo; the effects of pharmacological doses of these drugs were then assessed. High concentrations of carboplatin and lobaplatin markedly inhibited Y79 RB cell proliferation in vitro. In addition, the lobaplatin group exhibited higher proportions of early-stage apoptotic cells than the carboplatin group, while no significant differences in the proportions of cells in the S phase were observed between the 2 groups, as shown by flow cytometry. Significant changes in the E2F1/Cdc25a/Cdk2 pathway in the RB cells were detected by RNA-seq following carboplatin or lobaplatin intervention. RT-qPCR, immunofluorescence and immunohistochemical analyses in vivo and in vitro demonstrated that the trends of drug-induced inhibition of tumor pathological changes may have been regulated through the E2F1/Cdc25a/Cdk2 pathway, and that lobaplatin was more effective than carboplatin in controlling tumors in vivo. On the whole, the findings of the present study demonstrate that lobaplatin is associated with lower cytotoxicity and exerts more prominent therapeutic effects than carboplatin on Y79 RB cells in vitro and in mice in vivo.

show abstract

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

Cited by 5 publications

References 41 publications

Research Progress of Metal Anticancer Drugs

Research Progress of Metal Anticancer Drugs

Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines

Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo

Contact Info

Product

Resources

About